Trial Profile

A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Uzatresgene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
Indications Gastric cancer; Oesophageal cancer
Focus Registrational; Therapeutic Use
Acronyms SURPASS-2
Sponsors Adaptimmune

Most Recent Events

23 Apr 2024 Status changed from active, no longer recruiting to discontinued.
25 Jan 2024 Results focusing on diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine,published in the Diabetes, Obesity and Metabolism
12 Oct 2023 This trial has been Discontinued in Spain according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com